Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity Academic Article uri icon

Overview

MeSH Major

  • Insulin Resistance
  • Longevity
  • Sirolimus

abstract

  • Rapamycin, an inhibitor of mechanistic target of rapamycin complex 1 (mTORC1), extends the life spans of yeast, flies, and mice. Calorie restriction, which increases life span and insulin sensitivity, is proposed to function by inhibition of mTORC1, yet paradoxically, chronic administration of rapamycin substantially impairs glucose tolerance and insulin action. We demonstrate that rapamycin disrupted a second mTOR complex, mTORC2, in vivo and that mTORC2 was required for the insulin-mediated suppression of hepatic gluconeogenesis. Further, decreased mTORC1 signaling was sufficient to extend life span independently from changes in glucose homeostasis, as female mice heterozygous for both mTOR and mLST8 exhibited decreased mTORC1 activity and extended life span but had normal glucose tolerance and insulin sensitivity. Thus, mTORC2 disruption is an important mediator of the effects of rapamycin in vivo.

publication date

  • March 30, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3324089

Digital Object Identifier (DOI)

  • 10.1126/science.1215135

PubMed ID

  • 22461615

Additional Document Info

start page

  • 1638

end page

  • 43

volume

  • 335

number

  • 6076